Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia

NCT04992949 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT04992949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2022
Completion date
December 4, 2023
Enrollment
42 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myeloproliferative syndrome